Document:

Exhibit 4.4

 

		 	
        ROSS MILLER

        Secretary of State

        204 North Carson Street
        Suite 1

        Carson City, Nevada
        99701-4520

        (775) 684-5708

        Website: www.nvsos.gov

 

	
        Amendment to

        Certificate of Designation

        After Issuance of Class or Series

        (PURSUANT TO NRS 78.1955)
	 

 

	USE BLACK INK ONLY - DO NOT HIGHLIGHT	ABOVE SPACE  IS FOR OFFICE USE ONLY

 

Certificate of Amendment to Certificate
of Designation

For Nevada Profit Corporations

(Pursuant
to NRS 78.1955 - After Issuance of Class or
Series)

 

	1:	Name of corporation:
	NANOVIRICIDES, INC.
	 
	2.	Stockholder approval pursuant to statute has been obtained.
	 	 
	3.	The class or series of stock being amended:
	Series A Convertible Preferred Stock
	 	 
	4.	By a resolution adopted by the board of directors, the certificate of designation is being amended as follows or the new class or series is:
	1.  Designation.  The designation of preferred stock created hereby shall be “Series A Convertible Preferred Stock,”  par value $0.001 per share (the “Series A Preferred Stock”.) and the number of shares constituting the Series A Preferred Stock shall be Eight Million Five Hundred Thousand (8,500,000) shares, par value $0.001 per share.

 

	5.	Effective date of filing: (optional)	 
	 	 	(must not be later than 90 days after the certificate is filed)

 

	6.	Signature: (required)

 

	X   /s/ Anil Diwan 	 
	Signature of Officer	 

 

Filing Fee: $175.00

 

IMPORTANT: Failure to include any of the above information
and submit with the proper fees may cause this filing to be rejected.

	This form must be accompanied by appropriate fees.	
        Nevada Secretary of State NRS Amend Designation
        – After

        Revised 1-5-15Exhibit 10.16

 

 

	To	Thursday, September 26, 2019.

 

Attn:

 

	 	Re:	Waiver Letter Regarding Conversion of Series A Shares

 

Ladies and Gentlemen:

 

Reference is made to
that certain Certificate of Designation of Rights and Preferences of Series A Convertible Preferred Stock, as amended (the “Designation”)
of NanoViricides, Inc., a Nevada corporation (the “Company”). Capitalized terms used but not defined in this letter
(this “Waiver Letter”) shall have the meanings assigned to such terms in the Designator.

 

1.                 Waiver
Provision. Section 5 of the Designation provides that the Holder may convert their Shares of Series A Preferred Stock,
at the Conversion Rate, upon a “Change of Control” of the Company as defined in the Certificate of Designation of
Series A stock.

 

2.                 Waiver. Holder hereby agrees to waive any and all conversion rights in the Designation until the earlier of: (a)
December 31, 2019, or (b) the date the Company amends its Articles of incorporation to increase its authorized number of shares
of Common Stock to not less than 150,000,000 shares (the “Authorized Increase”).

 

3.                 Company Covenants, Representations and Warranties. 

 

a.                 The Company shall use its best efforts to obtain shareholder approval for the Authorized Increase on or before December 31, 2019
pursuant to a duly called meeting at which the Board would recommend such approval. The Company hereby represents and warrants
that the Board has approved such Authorized Increase and the taking of all actions necessary or advisable to implement this Waiver,
and has determined that a simple majority in interest of the vote of all shareholders is sufficient to satisfy the shareholder
vote requirements for the Authorized Increase under applicable law or otherwise. Such approval shall not be amended or rescinded
without Holder’s approval.

 

b.                 While this waiver of conversion rights by the Holder is in effect, the Company shall not engage into any acts or events that would
trigger a conversion under the Certificate of Designation of Series A shares without consent of the Holder.

 

 

 

    Page 1
                                                                                      of 3

     

    

 

 

 

c.                 While this waiver of conversion rights by the Holder is in effect, the Company shall not engage into any act or acts, or enable
any events, that may have the effect of amending, modifying, changing, or canceling the Certificate of Designation of Series A
shares.

 

d.                 In the event that the Company does not increase its authorized number of shares of Common Stock to not less than 150,000,000 shares
(the “Authorized Increase”) on or before December 31, 2019, without limitation of any other remedies available to Holder,
the Company shall if requested by Holder negotiate promptly and in good faith with the Holder to replace the Series A certificates
with instruments of at least equal value, such value to be estimated as though there was no waiver in effect and as though the
Company had performed the Authorized Increase.

 

4.                 Acknowledgement. Except as expressly modified and superseded by this Amendment, the terms and provisions of this
Waiver Letter and any instruments executed in connection therewith are hereby ratified and confirmed and shall continue in full
force and effect.

 

a.                 Choice of Law. This Waiver Letter (including, but not limited to, the validity and enforceability hereof) shall be
governed by, and construed in accordance with, the laws of the State of Nevada.

 

5.                 Counterparts. This Waiver Letter may be executed by one or more of the parties hereto in any number of separate counterparts,
and all of such counterparts taken together shall be deemed to constitute one and the same instrument. Delivery of this Waiver
Letter by electronic mail or facsimile transmission shall be effective as delivery of a manually executed counterpart hereof.

 

[ Signature Page to Follow]

 

 

 

    Page 2
                                                                                      of 3

     

    

 

 

If the foregoing correctly
states your understanding with respect to the matters stated in this Waiver Letter, please acknowledge by signing in the space
provided below.

 

	 	Company:
	 	NANOVIRICIDES, INC.
	 	 	 
	 	 	 
	 	By:	 
	 	Name:
	 	Title:
	 	 	 
	 	Holder:
	 	THERACOUR PHARMA, INC.
	 	 	 
	 	 	 
	 	By:  	 
	 	Name:
	 	Title:

 

 

    Page 3 of 3Exhibit 4.1

 

 

ABEONA THERAPEUTICS INC.

 

FORM OF WARRANT TO PURCHASE COMMON STOCK

Number of Shares: [●]

(subject to adjustment)

 

	Warrant No. [●]	 	Original Issue Date: December [●], 2019

 

Abeona Therapeutics Inc., a Delaware corporation (the “Company”),
hereby certifies that, for good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, [●]
or its registered assigns (the “Holder”) is entitled, subject to the terms set forth below, to purchase from
the Company up to a total of [●] shares of Common Stock, $0.01 par value (the “Common Stock”), of the
Company (each such share, a “Warrant Share” and all such shares, the “Warrant Shares”) at
an exercise price per share equal to $0.0001 per share (as adjusted from time to time as provided in Section 9 herein,
the “Exercise Price”) upon surrender of this Warrant to Purchase Common Stock (including any Warrants to Purchase
Common Stock issued in exchange, transfer or replacement hereof, the “Warrant”) at any time and from time to
time on or after the date hereof (the “Original Issue Date”), subject to the following terms and conditions:

 

1. Definitions. For purposes of this Warrant, the following
terms shall have the following meanings:

 

(a) “Affiliate” means
any Person directly or indirectly controlled by, controlling or under common control with, a Holder, as such terms are used in
and construed under Rule 405 under the Securities Act, but only for so long as such control shall continue.

 

(b) “Commission” means
the United States Securities and Exchange Commission.

 

(c) “Closing Sale Price”
means, for any security as of any date, the last trade price for such security on the Principal Trading Market for such security
as reported by Bloomberg L.P. or, if such Principal Trading Market begins to operate on an extended hours basis and does not designate
the last trade price, then the last trade price of such security prior to 4:00 P.M., New York City time, as reported by Bloomberg
L.P., or if the security is not listed for trading on a national securities exchange or other trading market on the relevant date,
the last quoted bid price for the security in the over-the-counter market on the relevant date as reported by OTC Markets Group
Inc. (or a similar organization or agency succeeding to its functions of reporting prices). If the Closing Sale Price cannot be
calculated for a security on a particular date on any of the foregoing bases, the Closing Sale Price of such security on such date
shall be the fair market value as mutually determined by the Company and the Holder. If the Company and the Holder are unable to
agree upon the fair market value of such security, then the Board of Directors of the Company shall use its good faith judgment
to determine the fair market value. The Board of Directors’ determination shall be binding upon all parties absent demonstrable
error. All such determinations shall be appropriately adjusted for any stock dividend, stock split, stock combination or other
similar transaction during the applicable calculation period.

 

(d) “Principal Trading Market”
means the national securities exchange or other trading market on which the Common Stock is primarily listed on and quoted for
trading, which, as of the Original Issue Date, shall be the Nasdaq Global Select Market.

 

(e) “Registration Statement”
means the Company’s Registration Statement on Form S-3 (File No. 333-224867), declared effective on June 7, 2018.

 

(f) “Securities Act”
means the Securities Act of 1933, as amended.

 

(g) “Trading Day” means
any weekday on which the Principal Trading Market is open for trading. If the Common Stock is not listed or admitted for trading,
“Trading Day” means any day except any Saturday, any Sunday, any day that is a federal legal holiday in the United
States or any day on which banking institutions in New York City are authorized or required by law or other governmental action
to close.

 

    	 	 	 

     

    

 

(h) “Transfer Agent”
means American Stock Transfer & Trust Company, LLC, the Company’s transfer agent and registrar for the Common Stock,
and any successor appointed in such capacity.

 

2. Issuance of Securities; Registration of Warrants.
The Warrant, as initially issued by the Company, is offered and sold pursuant to the Registration Statement. As of the Original
Issue Date, the Warrant Shares are issuable under the Registration Statement. Accordingly, the Warrant and, assuming issuance pursuant
to the Registration Statement or an exchange meeting the requirements of Section 3(a)(9) of the Securities Exchange Act of
1934, as amended (the “Exchange Act”), as in effect on the Original Issue Date, the Warrant Shares are not “restricted
securities” under Rule 144 promulgated under the Securities Act. The Company shall register ownership of this Warrant, upon
records to be maintained by the Company for that purpose (the “Warrant Register”), in the name of the record
Holder (which shall include the initial Holder or, as the case may be, any assignee to which this Warrant is assigned hereunder)
from time to time. The Company may deem and treat the registered Holder of this Warrant as the absolute owner hereof for the purpose
of any exercise hereof or any distribution to the Holder and for all other purposes, absent actual notice to the contrary.

 

3. Registration of Transfers. Subject to compliance with
all applicable securities laws, the Company shall, or will cause its Transfer Agent to, register the transfer of all or any portion
of this Warrant in the Warrant Register upon surrender of this Warrant and payment for all applicable transfer taxes (if any).
Upon any such registration or transfer, a new warrant to purchase Common Stock in substantially the form of this Warrant (any such
new warrant, a “New Warrant”) evidencing the portion of this Warrant so transferred shall be issued to the transferee,
and a New Warrant evidencing the remaining portion of this Warrant not so transferred, if any, shall be issued to the transferring
Holder. The acceptance of the New Warrant by the transferee thereof shall be deemed the acceptance by such transferee of all of
the rights and obligations in respect of the New Warrant that the Holder has in respect of this Warrant. The Company shall, or
will cause its Transfer Agent to, prepare, issue and deliver at the Company’s own expense any New Warrant under this Section 3.
Until due presentment for registration of transfer, the Company may treat the registered Holder hereof as the owner and holder
for all purposes, and the Company shall not be affected by any notice to the contrary.

 

4. Exercise and Duration of Warrants.

 

(a) All or any part of this Warrant shall
be exercisable by the registered Holder in any manner permitted by this Warrant at any time and from time to time on or after the
Original Issue Date.

 

(b) The Holder may exercise this Warrant
by delivering to the Company (i) an exercise notice in the form attached as Schedule 1 hereto (the “Exercise
Notice”), completed and duly signed, and (ii) payment of the Exercise Price for the number of Warrant Shares as
to which this Warrant is being exercised (which may take the form of a “cashless exercise” if so indicated in the Exercise
Notice pursuant to Section 10 below). The date on which such exercise notice is delivered to the Company (as determined
in accordance with the notice provisions hereof) is an “Exercise Date.” The Holder shall not be required to
deliver the original Warrant in order to effect an exercise hereunder. Execution and delivery of the Exercise Notice shall have
the same effect as cancellation of the original Warrant and issuance of a New Warrant evidencing the right to purchase the remaining
number of Warrant Shares, if any. The Holder and any assignee, by acceptance of this Warrant, acknowledge and agree that, by
reason of the provisions of this paragraph, following the purchase of a portion of the Warrant Shares hereunder, the number of
Warrant Shares available for purchase hereunder at any given time may be less than the amount stated on the face hereof.

 

5. Delivery of Warrant Shares.

 

(a) Upon exercise of this Warrant, the
Company shall promptly (but in no event later than three (3) Trading Days after the Exercise Date), upon the request of the
Holder, credit such aggregate number of shares of Common Stock to which the Holder is entitled pursuant to such exercise to the
Holder’s or its designee’s balance account with The Depository Trust Company (“DTC”) through its
Deposit Withdrawal Agent Commission system, or if the Transfer Agent is not participating in the Fast Automated Securities Transfer
Program (the “FAST Program”) or if the certificates are required to bear a legend regarding restriction on transferability,
issue and dispatch by overnight courier to the address as specified in the Exercise Notice, a certificate, registered in the Company’s
share register in the name of the Holder or its designee, for the number of shares of Common Stock to which the Holder is entitled
pursuant to such exercise. The Holder, or any natural person or legal entity (each, a “Person”) so designated
by the Holder to receive Warrant Shares, shall be deemed to have become the holder of record of such Warrant Shares as of the Exercise
Date, irrespective of the date such Warrant Shares are credited to the Holder’s DTC account or the date of delivery of the
certificates evidencing such Warrant Shares, as the case may be.

 

    	 	 	 

     

    

 

(b) If by the close of the third (3rd)
Trading Day after the Exercise Date, the Company fails to deliver to the Holder a certificate representing the required number
of Warrant Shares in the manner required pursuant to Section 5(a) or fails to credit the Holder’s DTC account for
such number of Warrant Shares to which the Holder is entitled, and if after such third (3rd) Trading Day and prior to the receipt
of such Warrant Shares, the Holder purchases (in an open market transaction or otherwise) shares of Common Stock to deliver in
satisfaction of a sale by the Holder of the Warrant Shares that the Holder anticipated receiving upon such exercise (a “Buy-In”),
then the Company shall, within three (3) Trading Days after the Holder’s written request and in the Holder’s sole discretion,
either (i) pay in cash to the Holder an amount equal to the Holder’s total purchase price (including brokerage commissions,
if any) for the shares of Common Stock so purchased, at which point the Company’s obligation to deliver such certificate
(and to issue such Warrant Shares) shall terminate or (ii) promptly honor its obligation to deliver to the Holder a certificate
or certificates representing such Warrant Shares and pay cash to the Holder in an amount equal to the excess (if any) of Holder’s
total purchase price (including brokerage commissions, if any) for the shares of Common Stock so purchased in the Buy-In over the
product of (A) the number of shares of Common Stock purchased in the Buy-In, times (B) the Closing Sale Price of a share of Common
Stock on the Exercise Date.

 

(c) To the extent permitted by law and
except to the extent the Company has fully performed its obligations under the provisions of Section 5(b) with respect to
a particular delivery failure thereunder, the Company’s obligations to issue and deliver Warrant Shares in accordance with
and subject to the terms hereof (including the limitations set forth in Section 11 below) are absolute and unconditional,
irrespective of any action or inaction by the Holder to enforce the same, any waiver or consent with respect to any provision hereof,
the recovery of any judgment against any Person or any action to enforce the same, or any setoff, counterclaim, recoupment, limitation
or termination, or any breach or alleged breach by the Holder or any other Person of any obligation to the Company or any violation
or alleged violation of law by the Holder or any other Person, and irrespective of any other circumstance that might otherwise
limit such obligation of the Company to the Holder in connection with the issuance of Warrant Shares. Except to the extent the
Company has fully performed its obligations under the provisions of Section 5(b) with respect to a particular delivery failure,
nothing herein shall limit the Holder’s right to pursue any other remedies available to it hereunder, at law or in equity
including, without limitation, a decree of specific performance and/or injunctive relief with respect to the Company’s failure
to timely deliver certificates representing shares of Common Stock upon exercise of the Warrant as required pursuant to the terms
hereof.

 

6. Charges, Taxes and Expenses. Issuance and delivery
of certificates for shares of Common Stock upon exercise of this Warrant shall be made without charge to the Holder for any issue
or transfer tax, transfer agent fee or other incidental tax or expense (excluding any applicable stamp duties) in respect of the
issuance of such certificates, all of which taxes and expenses shall be paid by the Company; provided, however, that
the Company shall not be required to pay any tax that may be payable in respect of any transfer involved in the registration of
any certificates for Warrant Shares or the Warrants in a name other than that of the Holder or an Affiliate thereof. The Holder
shall be responsible for all other tax liability that may arise as a result of holding or transferring this Warrant or receiving
Warrant Shares upon exercise hereof.

 

7. Replacement of Warrant. If this Warrant is mutilated,
lost, stolen or destroyed, the Company shall issue or cause to be issued in exchange and substitution for and upon cancellation
hereof, or in lieu of and substitution for this Warrant, a New Warrant, but only upon receipt of evidence reasonably satisfactory
to the Company of such loss, theft or destruction (in such case) and, in each case, a customary and reasonable indemnity and surety
bond, if requested by the Company. Applicants for a New Warrant under such circumstances shall also comply with such other reasonable
regulations and procedures and pay such other reasonable third-party costs as the Company may prescribe. If a New Warrant is requested
as a result of a mutilation of this Warrant, then the Holder shall deliver such mutilated Warrant to the Company as a condition
precedent to the Company’s obligation to issue the New Warrant.

 

    	 	 	 

     

    

 

8. Reservation of Warrant Shares. The Company covenants
that it will, at all times while this Warrant is outstanding, reserve and keep available out of the aggregate of its authorized
but unissued and otherwise unreserved Common Stock, solely for the purpose of enabling it to issue Warrant Shares upon exercise
of this Warrant as herein provided, the number of Warrant Shares that are initially issuable and deliverable upon the exercise
of this entire Warrant, free from preemptive rights or any other contingent purchase rights of persons other than the Holder (taking
into account the adjustments and restrictions of Section 9). The Company covenants that all Warrant Shares so issuable
and deliverable shall, upon issuance and the payment of the applicable Exercise Price in accordance with the terms hereof, be duly
and validly authorized, issued and fully paid and non-assessable. The Company will take all such action as may be reasonably necessary
to assure that such shares of Common Stock may be issued as provided herein without violation of any applicable law or regulation,
or of any requirements of any securities exchange or automated quotation system upon which the Common Stock may be listed. The
Company further covenants that it will not, without the prior written consent of the Holder, take any actions to increase the par
value of the Common Stock at any time while this Warrant is outstanding.

 

9. Certain Adjustments. The Exercise Price and number
of Warrant Shares issuable upon exercise of this Warrant are subject to adjustment from time to time as set forth in this Section 9.

 

(a) Stock Dividends and Splits.
If at any time while this Warrant is outstanding, the Company (i) pays a stock dividend on its Common Stock or otherwise makes
a distribution on any class of capital stock issued and outstanding on the Original Issue Date and in accordance with the terms
of such stock on the Original Issue Date, as described in the Registration Statement, that is payable in shares of Common Stock,
(ii) subdivides its outstanding shares of Common Stock into a larger number of shares of Common Stock, (iii) combines
its outstanding shares of Common Stock into a smaller number of shares of Common Stock or (iv) issues by reclassification
of shares of capital stock any additional shares of Common Stock of the Company, then in each such case the Exercise Price shall
be multiplied by a fraction, the numerator of which shall be the number of shares of Common Stock outstanding immediately before
such event and the denominator of which shall be the number of shares of Common Stock outstanding immediately after such event.
Any adjustment made pursuant to clause (i) of this paragraph shall become effective immediately after the record date for
the determination of stockholders entitled to receive such dividend or distribution, provided, however, that if such record date
shall have been fixed and such dividend is not fully paid on the date fixed therefor, the Exercise Price shall be recomputed accordingly
as of the close of business on such record date and thereafter the Exercise Price shall be adjusted pursuant to this paragraph
as of the time of actual payment of such dividends. Any adjustment pursuant to clause (ii) or (iii) of this paragraph shall
become effective immediately after the effective date of such subdivision or combination.

 

(b) Pro Rata Distributions. If at
any time while this Warrant is outstanding, the Company distributes to all holders of Common Stock for no consideration (i) evidences
of its indebtedness, (ii) any security (other than a distribution of Common Stock covered by the preceding paragraph) (iii) rights
or warrants to subscribe for or purchase any security, or (iv) cash or any other asset (in each case, a “Distribution”),
other than a reclassification as to which Section 9(c) applies, then in each such case, the Holder shall be entitled
to participate in such Distribution to the same extent that the Holder would have participated therein if the Holder had held the
number of shares of Common Stock acquirable upon complete exercise of this Warrant (without regard to any limitations on exercise
hereof, including without limitation, the ownership limitation set forth in Section 11(a) hereof) immediately before
the date of which a record is taken for such Distribution, or, if no such record is taken, the date as of which the record holders
of Common Stock are to be determined for the participation in such Distribution (provided, however, to the extent that the Holder’s
right to participate in any such Distribution would result in the Holder exceeding the ownership limitation set forth in Section 11(a)
hereof, then the Holder shall not be entitled to participate in such Distribution to such extent (or in the beneficial ownership
of any Common Stock as a result of such Distribution to such extent) and the portion of such Distribution shall be held in abeyance
for the benefit of the Holder until the earlier of (i) such time, if ever, as the delivery to such Holder of such portion
would not result in the Holder exceeding the ownership limitation set forth in Section 11(a) hereof and (ii) such
time as the Holder has exercised this Warrant.

 

    	 	 	 

     

    

 

(c) Fundamental Transactions. If
at any time while this Warrant is outstanding, (i) the Company effects any merger or consolidation of the Company with or
into another Person, in which the Company is not the surviving entity and in which the stockholders of the Company immediately
prior to such merger or consolidation do not own, directly or indirectly, at least 50% of the voting power of the surviving entity
immediately after such merger or consolidation, (ii) the Company effects any sale to another Person of all or substantially
all of its assets in one transaction or a series of related transactions, (iii) pursuant to any tender offer or exchange offer
(whether by the Company or another Person), holders of capital stock tender shares representing more than 50% of the voting power
of the capital stock of the Company and the Company or such other Person, as applicable, accepts such tender for payment, (iv) the
Company consummates a stock purchase agreement or other business combination (including, without limitation, a reorganization,
recapitalization, spin-off or scheme of arrangement) with another Person whereby such other Person acquires more than the 50% of
the voting power of the capital stock of the Company (except for any such transaction in which the stockholders of the Company
immediately prior to such transaction maintain, in substantially the same proportions, the voting power of such Person immediately
after the transaction) or (v) the Company effects any reclassification of the Common Stock or any compulsory share exchange
pursuant to which the Common Stock is effectively converted into or exchanged for other securities, cash or property (other than
as a result of a subdivision or combination of shares of Common Stock covered by Section 9(a) above) (in any such case,
a “Fundamental Transaction”), then following such Fundamental Transaction the Holder shall have the right to
receive, upon exercise of this Warrant, the same amount and kind of securities, cash or property as it would have been entitled
to receive upon the occurrence of such Fundamental Transaction if it had been, immediately prior to such Fundamental Transaction,
the holder of the number of Warrant Shares then issuable upon exercise in full of this Warrant without regard to any limitations
on exercise contained herein (the “Alternate Consideration”). The Company shall not effect any Fundamental Transaction
in which the Company is not the surviving entity or the Alternate Consideration includes securities of another Person unless (i) the
Alternate Consideration is solely cash and the Company provides for the simultaneous “cashless exercise” of this Warrant
pursuant to Section 10 below or (ii) prior to or simultaneously with the consummation thereof, any successor to
the Company, surviving entity or other Person (including any purchaser of assets of the Company) shall assume the obligation to
deliver to the Holder such Alternate Consideration as, in accordance with the foregoing provisions, the Holder may be entitled
to receive, and the other obligations under this Warrant. The provisions of this paragraph (c) shall similarly apply to subsequent
transactions analogous of a Fundamental Transaction type.

 

(d) Number of Warrant Shares. Simultaneously
with any adjustment to the Exercise Price pursuant to Section 9 (including any adjustment to the Exercise Price that
would have been effected but for the final sentence in this paragraph (d)), the number of Warrant Shares that may be purchased
upon exercise of this Warrant shall be increased or decreased proportionately, so that after such adjustment the aggregate Exercise
Price payable hereunder for the increased or decreased number of Warrant Shares shall be the same as the aggregate Exercise Price
in effect immediately prior to such adjustment. Notwithstanding the foregoing, in no event may the Exercise Price be adjusted below
the par value of the Common Stock then in effect.

 

(e) Calculations. All calculations
under this Section 9 shall be made to the nearest one-hundredth of one cent or the nearest share, as applicable.

 

(f) Notice of Adjustments. Upon
the occurrence of each adjustment pursuant to this Section 9, the Company at its expense will, at the written request
of the Holder, promptly compute such adjustment, in good faith, in accordance with the terms of this Warrant and prepare a certificate
setting forth such adjustment, including a statement of the adjusted Exercise Price and adjusted number or type of Warrant Shares
or other securities issuable upon exercise of this Warrant (as applicable), describing the transactions giving rise to such adjustments
and showing in detail the facts upon which such adjustment is based. Upon written request, the Company will promptly deliver a
copy of each such certificate to the Holder and to the Company’s transfer agent.

 

    	 	 	 

     

    

 

(g) Notice of Corporate Events.
If, while this Warrant is outstanding, the Company (i) declares a dividend or any other distribution of cash, securities or
other property in respect of its Common Stock, including, without limitation, any granting of rights or warrants to subscribe for
or purchase any capital stock of the Company or any subsidiary, (ii) authorizes or approves, enters into any agreement contemplating
or solicits stockholder approval for any Fundamental Transaction or (iii) authorizes the voluntary dissolution, liquidation
or winding up of the affairs of the Company, then, except if such notice and the contents thereof shall be deemed to constitute
material non-public information, the Company shall deliver to the Holder a notice of such transaction at least ten (10) days
prior to the applicable record or effective date on which a Person would need to hold Common Stock in order to participate in or
vote with respect to such transaction; provided, however, that the failure to deliver such notice or any defect therein shall not
affect the validity of the corporate action required to be described in such notice. In addition, if while this Warrant is outstanding,
the Company authorizes or approves, enters into any agreement contemplating or solicits stockholder approval for any Fundamental
Transaction contemplated by Section 9(c), other than a Fundamental Transaction under clause (iii) of Section 9(c),
then, except if such notice and the contents thereof shall be deemed to constitute material non-public information, the Company
shall deliver to the Holder a notice of such Fundamental Transaction at least ten (10) days prior to the date such Fundamental
Transaction is consummated.

 

10. Payment of Cashless Exercise Price. Notwithstanding
anything contained herein to the contrary, the Holder may, in its sole discretion, satisfy its obligation to pay the Exercise Price
through a “cashless exercise,” in which event the Company shall issue to the Holder the number of Warrant Shares in
an exchange of securities effected pursuant to Section 3(a)(9) of the Securities Act as determined as follows:

 

X = Y [(A-B)/A]

 

where:

 

“X” equals the number of Warrant
Shares to be issued to the Holder;

 

“Y” equals the total number
of Warrant Shares with respect to which this Warrant is then being exercised;

 

“A” equals the Closing Sale
Price per share of Common Stock as of the Trading Day on the date immediately preceding the Exercise Date; and

 

“B” equals the Exercise Price
per Warrant Share then in effect on the Exercise Date.

 

For purposes of Rule 144 promulgated under the Securities Act,
it is intended, understood and acknowledged that the Warrant Shares issued in such a “cashless exercise” transaction
shall be deemed to have been acquired by the Holder, and the holding period for the Warrant Shares shall be deemed to have commenced,
on the Original Issue Date (provided that the Commission continues to take the position that such treatment is proper at the time
of such exercise). In the event that the Registration Statement or another registration statement registering the issuance of Warrant
Shares is, for any reason, not effective at the time of exercise of this Warrant, then this Warrant may only be exercised through
a cashless exercise, as set forth in this Section 10.

 

In no event will the exercise of this Warrant be settled in
cash.

 

11. Limitations on Exercise.

 

(a) Notwithstanding anything to the contrary
contained herein (but subject to Section 11(b)), the Company shall not effect any exercise of this Warrant, and the Holder
shall not be entitled to exercise this Warrant for a number of Warrant Shares in excess of that number of Warrant Shares that,
upon giving effect or immediately prior to such exercise, would cause (i) the aggregate number of shares of Common Stock beneficially
owned by the Holder, its Affiliates and any other Persons whose beneficial ownership of Common Stock would be aggregated with the
Holder’s for purposes of Section 13(d) of the Exchange Act to exceed 9.99% (the “Maximum Percentage”)
of the total number of issued and outstanding shares of Common Stock of the Company following such exercise, or (ii) the combined
voting power of the securities of the Company beneficially owned by the Holder and its Affiliates and any other Persons whose beneficial
ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d) of the Exchange Act to
exceed 9.99% of the combined voting power of all of the securities of the Company then outstanding following such exercise. For
purposes of this Warrant, in determining the number of outstanding shares of Common Stock, the Holder may rely on the number of
outstanding shares of Common Stock as reflected in (x) the Company’s most recent Form 10-Q or Form 10-K, as the case
may be, filed with the Commission prior to the date hereof, (y) a more recent public announcement by the Company or (z) any
other notice by the Company or its transfer agent setting forth the number of shares of Common Stock outstanding. Upon the written
request of the Holder, the Company shall within three (3) Trading Days confirm in writing or by electronic mail to the Holder
the number of shares of Common Stock then outstanding. In any case, the number of outstanding shares of Common Stock shall be determined
after giving effect to the conversion or exercise of securities of the Company, including this Warrant, by the Holder since the
date as of which such number of outstanding shares of Common Stock was reported. For purposes of this Section 11(a),
the aggregate number of shares of Common Stock or voting securities beneficially owned by the Holder and its Affiliates and any
other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d)
of the Exchange Act shall include the shares of Common Stock issuable upon the exercise of this Warrant with respect to which such
determination is being made, but shall exclude the number of shares of Common Stock that would be issuable upon (x) exercise
of the remaining unexercised and non-cancelled portion of this Warrant by the Holder and (y) exercise or conversion of the
unexercised, non-converted or non-cancelled portion of any other securities of the Company that do not have voting power (including
without limitation any securities of the Company that would entitle the holder thereof to acquire at any time Common Stock, including
without limitation any debt, preferred stock, right, option, warrant or other instrument that is at any time convertible into or
exercisable or exchangeable for, or otherwise entitles the holder thereof to receive, Common Stock), is subject to a limitation
on conversion or exercise analogous to the limitation contained herein and is beneficially owned by the Holder or any of its Affiliates
and other Persons whose beneficial ownership of Common Stock would be aggregated with the Holder’s for purposes of Section 13(d)
of the Exchange Act.

 

    	 	 	 

     

    

 

(b) Nothing in Section 11(a)
shall in any manner restrict or limit the Alternate Consideration that a Holder shall be entitled to receive pursuant to Section
9(c) upon the occurrence of a Fundamental Transaction.

 

12. No Fractional Shares. No fractional Warrant Shares
will be issued in connection with any exercise of this Warrant. In lieu of any fractional shares that would otherwise be issuable,
the number of Warrant Shares to be issued shall be rounded down to the next whole number and the Company shall pay the Holder in
cash the fair market value (based on the Closing Sale Price) for any such fractional shares.

 

13. Notices. Any and all notices or other communications
or deliveries hereunder (including, without limitation, any Exercise Notice) shall be in writing and shall be deemed given and
effective on the earliest of (i) the date of transmission, if such notice or communication is delivered via facsimile or confirmed
e-mail prior to 5:30 P.M., New York City time, on a Trading Day, (ii) the next Trading Day after the date of transmission,
if such notice or communication is delivered via facsimile or confirmed e-mail on a day that is not a Trading Day or later than
5:30 P.M., New York City time, on any Trading Day, (iii) the Trading Day following the date of mailing, if sent by nationally
recognized overnight courier service specifying next business day delivery, or (iv) upon actual receipt by the Person to whom
such notice is required to be given, if by hand delivery. The addresses, facsimile numbers and e-mail addresses for such communications
shall be:

 

If to the Company:

 

Abeona Therapeutics Inc.

Attention: Edward Sturchio

1330 Avenue of the Americas, 33rd Floor,

New York, NY 10019

 

with a copy to:

 

Morgan, Lewis & Bockius LLP

One Federal Street

Boston, MA 02110

Attention: John Concannon III

 

If to the Holder, to its address, facsimile number
or e-mail address set forth herein or on the books and records of the Company,

 

or, in each of the above instances, to such other address, facsimile
number or e-mail address as the recipient party has specified by written notice given to each other party at least five (5) days
prior to the effectiveness of such change.

 

    	 	 	 

     

    

 

14. Warrant Agent. The Company shall initially serve
as warrant agent under this Warrant. Upon ten (10) days’ notice to the Holder, the Company may appoint a new warrant agent.
Any corporation into which the Company or any new warrant agent may be merged or any corporation resulting from any consolidation
to which the Company or any new warrant agent shall be a party or any corporation to which the Company or any new warrant agent
transfers substantially all of its corporate trust or shareholders services business shall be a successor warrant agent under this
Warrant without any further act. Any such successor warrant agent shall promptly cause notice of its succession as warrant agent
to be mailed (by first class mail, postage prepaid) to the Holder at the Holder’s last address as shown on the Warrant Register.

 

15. Miscellaneous.

 

(a) No Rights as a Stockholder.
The Holder, solely in such Person’s capacity as a holder of this Warrant, shall not be entitled to vote or receive dividends
or be deemed the holder of share capital of the Company for any purpose, nor shall anything contained in this Warrant be construed
to confer upon the Holder, solely in such Person’s capacity as the Holder of this Warrant, any of the rights of a stockholder
of the Company or any right to vote, give or withhold consent to any corporate action (whether any reorganization, issue of stock,
reclassification of stock, consolidation, merger, amalgamation, conveyance or otherwise), receive notice of meetings, receive dividends
or subscription rights, or otherwise, prior to the issuance to the Holder of the Warrant Shares that such Person is then entitled
to receive upon the due exercise of this Warrant. In addition, nothing contained in this Warrant shall be construed as imposing
any liabilities on the Holder to purchase any securities (upon exercise of this Warrant or otherwise) or as a stockholder of the
Company, whether such liabilities are asserted by the Company or by creditors of the Company.

 

(b) Authorized Shares. Except and
to the extent as waived or consented to by the Holder, the Company shall not by any action, including, without limitation, amending
its certificate or articles of incorporation or through any reorganization, transfer of assets, consolidation, merger, dissolution,
issue or sale of securities or any other voluntary action, avoid or seek to avoid the observance or performance of any of the terms
of this Warrant, but will at all times in good faith assist in the carrying out of all such terms and in the taking of all such
actions as may be necessary or appropriate to protect the rights of Holder as set forth in this Warrant against impairment. Without
limiting the generality of the foregoing, the Company will (a) not increase the par value of any Warrant Shares above the
amount payable therefor upon such exercise immediately prior to such increase in par value, (b) take all such action as may
be necessary or appropriate in order that the Company may validly and legally issue fully paid and non-assessable Warrant Shares
upon the exercise of this Warrant, and (c) use commercially reasonable efforts to obtain all such authorizations, exemptions
or consents from any public regulatory body having jurisdiction thereof as may be necessary to enable the Company to perform its
obligations under this Warrant.

 

(c) Successors and Assigns. Subject
to compliance with applicable securities laws, this Warrant may be assigned by the Holder. This Warrant may not be assigned by
the Company without the written consent of the Holder, except to a successor in the event of a Fundamental Transaction. This Warrant
shall be binding on and inure to the benefit of the Company and the Holder and their respective successors and assigns. Subject
to the preceding sentence, nothing in this Warrant shall be construed to give to any Person other than the Company and the Holder
any legal or equitable right, remedy or cause of action under this Warrant. This Warrant may be amended only in writing signed
by the Company and the Holder, or their successors and assigns.

 

(d) Amendment and Waiver. Except
as otherwise provided herein, the provisions of the Warrants may be amended and the Company may take any action herein prohibited,
or omit to perform any act herein required to be performed by it, only if the Company has obtained the written consent of the Holder.

 

(e) Acceptance. Receipt of this
Warrant by the Holder shall constitute acceptance of and agreement to all of the terms and conditions contained herein.

 

    	 	 	 

     

    

 

(f) Governing Law; Jurisdiction.
ALL QUESTIONS CONCERNING THE CONSTRUCTION, VALIDITY, ENFORCEMENT AND INTERPRETATION OF THIS WARRANT SHALL BE GOVERNED BY AND CONSTRUED
AND ENFORCED IN ACCORDANCE WITH THE LAWS OF THE STATE OF NEW YORK WITHOUT REGARD TO THE PRINCIPLES OF CONFLICTS OF LAW THEREOF.
EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY SUBMITS TO THE EXCLUSIVE JURISDICTION OF THE STATE AND FEDERAL COURTS SITTING
IN THE CITY OF NEW YORK, BOROUGH OF MANHATTAN, FOR THE ADJUDICATION OF ANY DISPUTE HEREUNDER OR IN CONNECTION HEREWITH OR WITH
ANY TRANSACTION CONTEMPLATED HEREBY OR DISCUSSED HEREIN (INCLUDING WITH RESPECT TO THE ENFORCEMENT OF ANY OF THE TRANSACTION DOCUMENTS),
AND HEREBY IRREVOCABLY WAIVES, AND AGREES NOT TO ASSERT IN ANY SUIT, ACTION OR PROCEEDING, ANY CLAIM THAT IT IS NOT PERSONALLY
SUBJECT TO THE JURISDICTION OF ANY SUCH COURT. EACH OF THE COMPANY AND THE HOLDER HEREBY IRREVOCABLY WAIVES PERSONAL SERVICE OF
PROCESS AND CONSENTS TO PROCESS BEING SERVED IN ANY SUCH SUIT, ACTION OR PROCEEDING BY MAILING A COPY THEREOF VIA REGISTERED OR
CERTIFIED MAIL OR OVERNIGHT DELIVERY (WITH EVIDENCE OF DELIVERY) TO SUCH PERSON AT THE ADDRESS IN EFFECT FOR NOTICES TO IT AND
AGREES THAT SUCH SERVICE SHALL CONSTITUTE GOOD AND SUFFICIENT SERVICE OF PROCESS AND NOTICE THEREOF. NOTHING CONTAINED HEREIN SHALL
BE DEEMED TO LIMIT IN ANY WAY ANY RIGHT TO SERVE PROCESS IN ANY MANNER PERMITTED BY LAW. EACH OF THE COMPANY AND THE HOLDER HEREBY
WAIVES ALL RIGHTS TO A TRIAL BY JURY.

 

(g) Headings. The headings herein
are for convenience only, do not constitute a part of this Warrant and shall not be deemed to limit or affect any of the provisions
hereof.

 

(h) Severability. In case any one
or more of the provisions of this Warrant shall be invalid or unenforceable in any respect, the validity and enforceability of
the remaining terms and provisions of this Warrant shall not in any way be affected or impaired thereby, and the Company and the
Holder will attempt in good faith to agree upon a valid and enforceable provision which shall be a commercially reasonable substitute
therefor, and upon so agreeing, shall incorporate such substitute provision in this Warrant.

 

[REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

 

    	 	 	 

     

    

 

IN WITNESS WHEREOF, the Company has caused
this Warrant to be duly executed by its authorized officer as of the date first indicated above.

 

 

	 	ABEONA THERAPEUTICS INC.
	 	 	 
	 	 	 
	 	By: 	            
	 	 	Name: 
	 	 	Title: 

 

[Signature Page to Warrant]

 

    	 	 	 

     

    

 

SCHEDULE 1 

 

FORM OF EXERCISE NOTICE 

 

[To be executed by the Holder to purchase
shares of Common Stock under the Warrant]

 

Ladies and Gentlemen:

 

(1) The undersigned is the Holder of Warrant No.     
(the “Warrant”) issued by Abeona Therapeutics Inc., a Delaware corporation (the “Company”). Capitalized
terms used herein and not otherwise defined herein have the respective meanings set forth in the Warrant.

 

(2) The undersigned hereby exercises its right to purchase Warrant
Shares pursuant to the Warrant.

 

(3) The Holder intends that payment of the Exercise Price shall
be made as (check one):

 

	 	 ̈	Cash Exercise 

 

	 	 ̈	“Cashless Exercise” under Section 10 of the Warrant 

 

(4) If the Holder has elected a Cash Exercise, the Holder shall
pay the sum of $ __________ in immediately available funds to the Company in accordance with the terms of the Warrant.

 

(5) Pursuant to this Exercise Notice, the Company shall deliver
to the Holder such number of Warrant Shares determined in accordance with the terms of the Warrant. The Warrant Shares shall be
delivered to the following DWAC Account Number:

 

                          
                                      

 

(6) By its delivery of this Exercise Notice, the undersigned
represents and warrants to the Company that in giving effect to the exercise evidenced hereby, the Holder will not beneficially
own in excess of the number of shares of Common Stock (as determined in accordance with Section 13(d) of the Securities Exchange
Act of 1934, as amended) permitted to be owned under Section 11(a) of the Warrant to which this notice relates.

 

	Dated:	 	 
	 	 	 
	Name of Holder:  	 	 
	 	 	 
	By:	 	 
	 	 	 
	Name:	 	 
	 	 	 
	Title:	 	 

 

(Signature must conform in all respects
to name of Holder as specified on the face of the Warrant)

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}], [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00303-of-00352.parquet"}]]